Degron Therapeutics extends Series A as DEG6498 enters the harder phase of cancer drug validation
Molecular glue funding is back, but clinic data remain thin. Degron’s HuR bet now faces the proof burden in solid tumors.
How Amphista Therapeutics is positioning non-cereblon degraders for next-generation oncology pipelines
Discover how Amphista Therapeutics’ SMARCA2 and TEAD degrader data could redefine targeted cancer therapies. Read the full analysis now.
Can Orum Therapeutics crack one of AML’s hardest problems with ORM-1153? AACR 2026 data spark fresh attention
Orum Therapeutics unveiled AACR 2026 data for ORM-1153 in AML. Read why the CD123 degrader strategy could matter for efficacy and tolerability.
Triana Biomedicines tests degradation-first approach in ALK positive lung cancer with TRI-611
Triana Biomedicines launches TRI-611 trial in ALK lung cancer. Can molecular glue degraders overcome resistance? Read the full analysis.
How Orum Therapeutics plans to solve GSPT1 toxicity with a DAC approach in AML
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.